 Home > Medical News > Latest Medical News > Junshi Biology JS019 Injection Obtained the Notification of Acceptance of Drug Clinical Trial Application

Junshi Biology JS019 Injection Obtained the Notification of Acceptance of Drug Clinical Trial Application

 Last Update: 2021-11-16
 Source: Internet
 Author: User

Tags

target picture development

pyrimethamine side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 21st, Junshi Biological issued an announcement stating that Suzhou Kebrijun Biomedical Technology Co.

The active ingredient of JS019 injection is recombinant fully human anti-CD39 monoclonal antibody

In September 2020, the company entered into a cooperation agreement with Beijing Enruini to jointly establish Suzhou Keboruijun to be responsible for the development, clinical application and commercialization of CD39 drugs

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.